Company Summary - Avacta Group PLC (LSE:AVCT)
1.62p
0.00p
Pharmaceuticals & BiotechnologyMarket cap: £20.977m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Biophysics company developing technology products
| Financials - Annual Report (31/07/2009) | ||
|---|---|---|
| Turnover | £m | 0.94 |
| Pre-tax Profit | £m | -2.84 |
| EPS | p | -0.18 |
| DPS | p | - |
| Dividend Yield | % | |
| Director | Board Role |
|---|---|
| Dr. Gwyn Humphreys | Chairman |
| Prof. Alastair Smith | Chief Executive |
| Tim Sykes | Finance Director & Company Sec |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
Avacta Ltd; Avacta Analytical Ltd; Oxford Medical Diagnostics Ltd; Curidium Medica Ltd; Curidium Ltd; Avacta Animal Health Ltd...
Broker Sentiment (1 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Notice of Results and Trading Update | 08/03/2010 |
| Acquisition | 03/03/2010 |
| Director/PDMR Shareholding | 22/02/2010 |